12:07 PM EST, 01/09/2025 (MT Newswires) -- Rigel Pharmaceuticals ( RIGL ) said Thursday that the US Food and Drug Administration granted orphan drug designation to R289 for treatment of patients with myelodysplastic syndromes, or MDS.

The company said it is conducting a phase 1b study to evaluate the investigational drug's safety, tolerability, pharmacokinetics and preliminary activity in MDS.

FDA's orphan drug designation makes the recipient eligible for tax credits, exemption from certain fees and up to seven years of market exclusivity following drug approval.

Price: 16.25, Change: -0.84, Percent Change: -4.92